<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102597">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02021760</url>
  </required_header>
  <id_info>
    <org_study_id>RECOND</org_study_id>
    <nct_id>NCT02021760</nct_id>
  </id_info>
  <brief_title>Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction</brief_title>
  <acronym>RECOND</acronym>
  <official_title>Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction in Stockholm (RECOND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Pernow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Trial objective: To test the hypothesis that remote per-postconditioning in connection
           with primary PCI will reduce myocardial infarct size patients with STEMI.

        -  Trial Design: Placebo controlled randomized study with parallel groups

        -  Primary Endpoint: Myocardial infarct size expressed as a percentage of the myocardium
           at risk determined by Cardiac Magnetic Resonance (CMR) day 4-7

        -  Efficacy Parameters: Myocardial infarct size expressed as a percentage to the
           myocardium at risk determined by CMR at 6 months.

        -  Global left ventricular function determined by left ventricular ejection fraction
           determined by CMR.

        -  Microvascular obstruction determined by CMR day 4-7. Quantified ECV (extracellular
           volume) in left ventricular as myocardium at risk day 4-7 and remodelling parameters
           day 180.

        -  Safety Parameters: Major adverse cardiovascular events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance</measure>
    <time_frame>4-7 days following index event</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance</measure>
    <time_frame>6 months following index event</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Global left ventricular function determined by left ventricular ejection fraction determined by CMR.</measure>
    <time_frame>4-7 days and 6 months following index event</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular obstruction determined by CMR</measure>
    <time_frame>4-7 days following index event</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Quantified ECV (extracellular volume) in left ventricular as myocardium at risk</measure>
    <time_frame>4-7 days following index event</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarct size by CMR expressed as a percentage to the myocardium at risk determined by Bari or modified Approach Score with coronary angiography.</measure>
    <time_frame>5-7 days following index event</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Remote Ischemic per-postconditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote conditioning is induced by inflation of a blood pressure  cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if &gt;180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham procedures include application of the cuff around the thigh but it is not inflated</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary Percutaneous Coronary Intervention</intervention_name>
    <arm_group_label>Remote Ischemic per-postconditioning</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient planned for primary PCI.

          -  Chest pain indicating myocardial ischemia with a duration &gt;30 minutes and &lt; 6 hours
             prior to randomization.

          -  ST elevations &gt;0.1 mV (&gt;0.2 mV in V2-V3) in &gt; two contiguous leads in V1-V6.

          -  Informed consent.

        Exclusion Criteria:

          -  Previous myocardial infarction based on medical history or Q-wave on ECG in other
             area

          -  Left Bundle Branch Block on ECG.

          -  Previous CABG

          -  Cardiac arrest

          -  Any contraindication for CMR.

          -  Clinical symptoms of claudication

          -  Treatment with glibenclamide or cyclosporine on admission.

          -  Any condition that may interfere with the possibility for the patient to comply with
             or complete the study protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pernow, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Pernow, Professor</last_name>
    <email>john.pernow@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Felix Bohm, PhD, MD</last_name>
    <email>felix.bohm@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pernow, Professor</last_name>
      <email>john.pernow@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Felix Bohm, MD, PhD</last_name>
      <email>felix.bohm@ki.se</email>
    </contact_backup>
    <investigator>
      <last_name>John Pernow, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Bohm, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dinos Verouhis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loghman Henareh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peder Sorensson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nawsad Saleh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Gonon, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Persson</last_name>
      <email>jonas.persson@ds.se</email>
    </contact>
    <investigator>
      <last_name>Jonas Persson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SÃ¶dersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Witt, MD, PhD</last_name>
      <email>nils.witt@sodersjukhuset.se</email>
    </contact>
    <contact_backup>
      <last_name>Per Tornvall, MD, PhD</last_name>
      <email>per.tornvall@ki.se</email>
    </contact_backup>
    <investigator>
      <last_name>Nils Witt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Tornvall, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>John Pernow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
